Exploring Celldex Therapeutics, Inc. (CLDX) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Celldex Therapeutics, Inc. (CLDX) and, more importantly, why? With institutional investors holding a significant 72.4%, amounting to $385.6 million, and hedge funds accounting for 6.3% or $33.5 million, it's clear that Celldex has captured the attention of some major players. Could their confidence stem from Celldex's innovative pipeline of antibody-based therapeutics, designed to tackle devastating diseases? Or is it the impressive 810.45% increase in stock price over the past 5 years that's drawing them in? Keep reading to uncover the detailed investor profile of Celldex and understand the motivations behind their investments.

Celldex Therapeutics, Inc. (CLDX) Who Invests in Celldex Therapeutics, Inc. (CLDX) and Why?

Understanding the investor profile of Celldex Therapeutics, Inc. (CLDX) involves examining the diverse range of investors and their motivations. These investors are attracted to Celldex Therapeutics, Inc. (CLDX) for various reasons, reflecting different investment strategies and expectations.

Key investor types include:

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies that invest on behalf of others.
• Hedge Funds: Investment partnerships that use pooled funds and employ various strategies to earn active return, or alpha, for their investors.

Each type of investor has different motivations and strategies that influence their investment decisions regarding Celldex Therapeutics, Inc. (CLDX).

Investment motivations for investing in Celldex Therapeutics, Inc. (CLDX) often include:

• Growth Prospects: Investors are often drawn to Celldex Therapeutics, Inc. (CLDX)’s potential for future growth, driven by its pipeline of drug candidates and potential market opportunities.
• Market Position: The company's standing in the biotechnology industry, including its competitive advantages and strategic partnerships, can attract investors.

The strategies employed by investors in Celldex Therapeutics, Inc. (CLDX) can vary widely:

• Long-Term Holding: Some investors adopt a long-term approach, holding shares for an extended period to benefit from the anticipated appreciation of the company's value.
• Short-Term Trading: Other investors engage in short-term trading, seeking to profit from short-term price fluctuations.
• Value Investing: Value investors are attracted to companies that they believe are undervalued by the market, purchasing shares with the expectation that the market will eventually recognize their true worth.

Institutional investors may hold a significant percentage of Celldex Therapeutics, Inc. (CLDX)'s shares. As of February 8, 2024, institutional investors held 78.60% of Celldex Therapeutics, Inc. (CLDX)'s shares.

Here is a breakdown of some of the top institutional holders and their positions as of December 31, 2023:

The data reflects the significant institutional interest in Celldex Therapeutics, Inc. (CLDX), potentially driven by the factors listed above such as growth prospects and market position.

For more insights into Celldex Therapeutics, Inc. (CLDX), explore: Celldex Therapeutics, Inc. (CLDX): History, Ownership, Mission, How It Works & Makes Money

Celldex Therapeutics, Inc. (CLDX) Institutional Ownership and Major Shareholders of Celldex Therapeutics, Inc. (CLDX)

Institutional ownership in Celldex Therapeutics, Inc. (CLDX) reflects the confidence and investment strategies of large financial entities. Examining the major shareholders and their recent activities provides valuable insights into the stock's potential performance and the company's strategic direction.

Here's a detailed look at the institutional ownership of Celldex Therapeutics, Inc. (CLDX):

Top Institutional Investors:

As of March 31, 2024, the top institutional holders of Celldex Therapeutics, Inc. (CLDX) included:

• Vanguard Group Inc: Holding 8,419,825 shares, representing 7.9% of the company.
• BlackRock Inc.: Holding 6,837,823 shares, representing 6.4% of the company.
• State Street Corp: Holding 3,374,525 shares, representing 3.2% of the company.
• Geode Capital Management, LLC: Holding 1,624,775 shares, representing about 1.5% of the company.
• Citadel Advisors LLC: Holding 1,488,491 shares, representing about 1.4% of the company.

These major institutional investors collectively hold a significant portion of Celldex Therapeutics, Inc. (CLDX), indicating strong institutional interest in the company's prospects.

Changes in Ownership:

Recent changes in institutional ownership can signal shifts in sentiment and future stock performance. For example:

• Vanguard Group Inc: Increased its holdings by 2.1% in the first quarter of 2024.
• BlackRock Inc.: Decreased its holdings by 4.6% in the first quarter of 2024.
• State Street Corp: Increased its holdings by 1.2% in the first quarter of 2024.

These adjustments in holdings can reflect each institution's evolving outlook on Celldex Therapeutics, Inc. (CLDX) based on factors like clinical trial results, market conditions, and overall investment strategy.

Impact of Institutional Investors:

Institutional investors play a crucial role in Celldex Therapeutics, Inc. (CLDX)'s stock price and strategy:

• Price Stability and Liquidity: Large institutional holdings typically provide more stability and liquidity to the stock.
• Strategic Influence: Major shareholders can influence corporate governance and strategic decisions through voting rights and engagement with company management.
• Market Confidence: Significant investments by reputable institutions can boost market confidence, attracting further investment.

Here is a summary table of the top institutional investors in Celldex Therapeutics, Inc. (CLDX) as of March 31, 2024:

Understanding the dynamics of institutional ownership in Celldex Therapeutics, Inc. (CLDX) is essential for investors. Monitoring these large stakeholders’ positions and their trading activity can offer valuable insights into potential shifts in market sentiment and the company’s future prospects.

For further insights into Celldex Therapeutics, Inc. (CLDX)'s financial health, consider exploring: Breaking Down Celldex Therapeutics, Inc. (CLDX) Financial Health: Key Insights for Investors

Celldex Therapeutics, Inc. (CLDX) Key Investors and Their Impact on Celldex Therapeutics, Inc. (CLDX)

Understanding the investor profile of Celldex Therapeutics, Inc. (CLDX) is crucial for grasping the dynamics influencing the company's stock performance and strategic decisions. Key investors can range from institutional giants to individual activist shareholders, each wielding varying degrees of influence.

While specific, real-time data on all investors and their recent moves fluctuates, examining publicly available information and reports from the 2024 fiscal year provides a valuable overview. Notable investors often include:

• Hedge Funds: These funds frequently take significant positions in biotech companies, aiming to capitalize on potential breakthroughs and market volatility. Their investment decisions can drive short-term stock movements.
• Mutual Funds: Large mutual funds often hold shares in Celldex Therapeutics, Inc. (CLDX) as part of broader healthcare or biotech portfolios. Their influence is typically more long-term, reflecting confidence in the company's overall prospects.
• Venture Capital Firms: Venture capital firms that previously invested in Celldex Therapeutics, Inc. (CLDX) during its early stages may still hold substantial stakes.
• Activist Investors: Although not always present, activist investors can acquire significant shares and push for changes in corporate governance or strategic direction.

The influence of these investors can manifest in several ways:

• Stock Price Volatility: Large purchases or sales by major investors can create significant price swings.
• Strategic Shifts: Activist investors might advocate for specific changes, such as focusing on particular drug candidates or exploring strategic partnerships.
• Corporate Governance: Major shareholders can influence board elections and key decisions regarding executive compensation and company policies.

Keeping track of recent moves by key investors is essential. This includes monitoring SEC filings (such as Form 4 filings for insider transactions and Schedule 13D/G filings for significant ownership stakes) to identify instances of buying or selling shares. For example, a large institutional investor increasing its stake could signal confidence in Celldex Therapeutics, Inc. (CLDX)'s future, while a significant sell-off might raise concerns.

Here is a hypothetical overview, based on the kind of information one might find in real-world financial reporting:

For more insights into Celldex Therapeutics, Inc. (CLDX), you might find this resource helpful: Mission Statement, Vision, & Core Values of Celldex Therapeutics, Inc. (CLDX).

Celldex Therapeutics, Inc. (CLDX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Celldex Therapeutics, Inc. (CLDX). This analysis encompasses recent ownership changes, market responses, and analyst perspectives to provide a comprehensive view of the company's current standing.

Here's a breakdown of key aspects:

• Investor Sentiment: The current sentiment among major shareholders appears mixed. While some institutions have increased their positions, others have reduced theirs. For example, Wellington Management Group Llp decreased its holdings by 2.98% in a recent filing, while Kynam Capital Management increased its stake by 31.70%. Overall, the number of funds or institutions reporting positions in Celldex Therapeutics has decreased slightly by 1.64% in the last quarter, with 419 funds or institutions reporting positions.
• Institutional Ownership: Institutional investors hold a significant portion of Celldex Therapeutics, Inc. (CLDX). As of recent filings, these institutions collectively hold 83,403,023 shares. Major shareholders include:
  • Wellington Management Group Llp with 8.98M shares, representing 13.53% ownership.
  • BlackRock, Inc. with 5.48M shares, holding 8.26%.
  • Kynam Capital Management, LP, owning 5.06M shares, which accounts for 7.63% ownership.
  • FMR Llc with 4.86M shares, or 7.32%.
  • Vanguard Group Inc. holding 3.88M shares, representing 5.85%.
• Hedge Fund Activity: By the end of Q2 2024, 34 hedge funds held positions in Celldex Therapeutics, Inc. Kynam Capital was the largest hedge fund investor, with a stake valued at over $125.4 million.

Recent Market Reactions:

• Stock Performance: Celldex Therapeutics, Inc. (CLDX) has experienced notable stock price volatility. As of April 17, 2025, the stock traded at $18.30, marking a 2.81% increase from the previous session. However, over the last year, the stock price has fallen by 52.50%.
• Market Cap: Today Celldex Therapeutics, Inc. has the market capitalization of ‪1.21 B‬, it has increased by 11.94% over the last week.
• Analyst Price Targets: Analysts' opinions on Celldex Therapeutics, Inc. future price vary. The average price target is $58.43. The highest estimate goes up to $90.00, while the lowest is $36.00.
• Short Interest: 13.00% of Celldex Therapeutics' floating shares are currently sold short.
• Earnings and Revenue: Celldex Therapeutics, Inc. (CLDX) revenue for the last quarter is $7.0M. The company's next earnings report is scheduled for May 1, 2025.

Analyst Perspectives:

• Ratings: Celldex Therapeutics's analyst rating consensus is a Strong Buy, based on ratings from Wall Street analysts.
• Price Targets: Analysts have provided a range of price targets, with an average 12-month target of $58.43.
• Projections: The projected annual revenue for Celldex Therapeutics is 2MM, a decrease of 74.72%. The projected annual non-GAAP EPS is -2.51.

Key Takeaways:

• The put/call ratio of CLDX is 1.32, indicating a bearish outlook.
• Celldex Therapeutics, Inc. (CLDX) has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
• Celldex Therapeutics, Inc. (CLDX) has 228.44% upside potential, based on the analysts' average price target.

See more about Celldex Therapeutics, Inc. (CLDX) Celldex Therapeutics, Inc. (CLDX): History, Ownership, Mission, How It Works & Makes Money